RAAISE: Rapid Access to ANA Testing in Indigenous Communities for Systemic Lupus Erythematosus

Summary

In our study, RAAISE, we will assess the logistics and effectiveness of using dried blood spots (DBS), saliva and urine as methods for screening for Lupus (systemic lupus erythematosus or SLE) and other systemic autoimmune rheumatic diseases (SARD), such as rheumatoid arthritis (RA) scleroderma or systemic sclerosis, Sjogren disease, autoimmune inflammatory myopathy and mixed connective tissue disease. These collection methods will offer a less invasive and more accessible method of screening for SARD in resource-limited and remote areas.

Participation in RAAISE involves providing blood through venipuncture, DBS (where blood from finger-prick testing is collected on a card), saliva and urine.

Currently recruiting Healthy controls and those with a confirmed diagnosis of a SARD. You do not need to be indigenous to participate.

Eligibility

Currently recruiting participants: Yes

Eligible ages: 18 to 99

Accepts healthy participants: Yes

Inclusion criteria:

Participants must be:
1) 18 years of age or older
2) able to read, write and speak English.
3) willing and able to provide blood, DBS, saliva and urine samples.
4) One of the following:

A) Have a confirmed diagnosis of a connective tissue disease: systemic lupus erythematosus (SLE), myositis, rheumatoid arthritis, scleroderma/systemic sclerosis, sjogren's disease, or others.
Or
B) be generally healthy, with
i) no history or symptoms of an autoimmune disease (tender and swollen joints) and
ii) have no family history of autoimmune disease.

Participate

Fill out the following form if you want to participate in this research

Method of contact

Additional information

Contact information

Prospective Participants can email ai.dx@ucalgary.ca to express their interest. Note that those with rheumatic disease will need their diagnosis confirmed through chart review to to be eligible. Healthy participants will fill out a screening questionnaire to confirm their eligibility.

Principal investigator:

May Choi

Clinical trial:

No

REB-ID:

REB24-0282